Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NUTROPIN DEPOT

« Back to Dashboard
Nutropin Depot is a drug marketed by Genentech and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and four patent family members in twenty-three countries.

The generic ingredient in NUTROPIN DEPOT is somatropin recombinant. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the somatropin recombinant profile page.

Summary for Tradename: NUTROPIN DEPOT

Patents:2
Applicants:1
NDAs:1

Clinical Trials for: NUTROPIN DEPOT

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Status: Terminated Condition: Growth Hormone Deficiency (GHD)

Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments
Status: Recruiting Condition: Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Status: Recruiting Condition: Adult Growth Hormone Deficiency

Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
Status: Completed Condition: Turner's Syndrome; Human Growth Hormone Deficiency

Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
Status: Completed Condition: Growth Hormone Deficiency

Effects of Short-term Growth Hormone in HIV-infected Patients
Status: Completed Condition: HIV Lipodystrophy

Clinical Trial of Growth Hormone in MPS I, II, and VI
Status: Terminated Condition: Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI

Observational Prospective Study on Patients Treated With Norditropin®
Status: Enrolling by invitation Condition: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Adult Growth Hormone Deficiency; Genetic Disorder; Turner Syndrome; Foetal Growth Problem; Small for Gestational Age; Chronic Kidney Disease; Chronic Renal Insufficiency; Noonan Syndrome

Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
Status: Completed Condition: Growth Hormone Deficiency

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-001Dec 22, 1999DISCNNo5,654,010<disabled><disabled>
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999DISCNNo5,654,010<disabled><disabled>
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-001Dec 22, 1999DISCNNo5,656,297<disabled><disabled>
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999DISCNNo5,656,297<disabled><disabled>
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999DISCNNo5,654,010<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: NUTROPIN DEPOT

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
5,654,010
NUTROPIN DEPOT
August 05, 2009
5,656,297
NUTROPIN DEPOT
August 12, 2009

Non-Orange Book Patents for Tradename: NUTROPIN DEPOT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,780,434 Controlled release of metal cation-stabilized interferon<disabled in preview>
5,716,644 Composition for sustained release of non-aggregated erythropoietin<disabled in preview>
6,555,525 Microencapsulation and sustained release of oligonucleotides<disabled in preview>
5,667,808 Composition for sustained release of human growth hormone<disabled in preview>
6,749,866 Modulated release from biocompatible polymers<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NUTROPIN DEPOT

Country Document Number Publication Date
China1177612Dec 01, 2004
Australia680422Jul 31, 1997
Hungary9900870Apr 28, 2001
Mexico9709699Jul 31, 1998
HungaryT77136Mar 02, 1998
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc